VIDEO: Study investigates exceptional treatment response in metastatic breast cancer
Click Here to Manage Email Alerts
SAN ANTONIO — In this video, Shimoli Barot, MD, discusses the results of a study observing exceptional treatment response in patients with metastatic breast cancer presented at San Antonio Breast Cancer Symposium.
The study observed the clinical, pathologic, genetic and genomic characteristics of metastatic breast cancer, and identified the combinations that influenced exceptional responses.
“[The] treatments that were associated with exceptional response were primarily endocrine therapy, CDK4/6 inhibitors, HER2-targeted therapies and combinations with capecitabine,” Barot, a medical oncologist at Cleveland Clinic Cancer Center, said. “A very small proportion of our patients had a significant family history, but we noted that a number of them carried germline genetic mutations, just highlighting how important it is to offer genetic testing and genetic counseling to these patients.”
Reference:
- Mohamed Hassan AN, et al. Abstract P5-12-30. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio.
Collapse
Healio Interviews
Click Here to Manage Email Alerts